EDP-323 for Drug Interaction
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests how a new treatment, EDP-323, interacts with three common substances: midazolam (a sedative), caffeine, and rosuvastatin (a cholesterol-lowering drug). The goal is to determine how EDP-323 affects the body's processing and safety of these substances. The trial seeks healthy adults without current illnesses and not taking medications that might interfere. Participants will receive all four substances during the trial to monitor any changes. As a Phase 1 trial, this research aims to understand how EDP-323 works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, since the study involves drug interactions, it's possible that some medications might need to be paused. Please consult with the trial coordinators for specific guidance.
Is there any evidence suggesting that EDP-323 is likely to be safe for humans?
Research has shown that EDP-323 is generally safe for people. In an earlier study, 14.6% of participants reported side effects, but most were mild and likely not caused by the drug. Some participants did experience side effects, but they were not serious and probably not due to EDP-323. As the treatment remains in early testing stages, researchers are closely monitoring safety. This focus on safety is a positive sign in understanding how safe EDP-323 is for people.12345
Why do researchers think this study treatment might be promising?
Most treatments for viral infections focus on directly attacking the virus or boosting the immune system. But EDP-323 works differently, targeting a specific protein that viruses use to replicate. This unique approach not only aims to stop the virus from multiplying but could also potentially make the treatment effective against a broader range of viral strains. Researchers are excited because this could lead to a more versatile and powerful way to manage viral infections, offering hope for quicker and more effective treatment options.
What evidence suggests that EDP-323 is effective for drug interaction?
Research has shown that EDP-323 may help treat respiratory syncytial virus (RSV) infections. Studies have found it can prevent RSV infection if taken within five days of exposure to the virus. Early results suggest it is safe and generally well-tolerated by healthy individuals. This treatment targets a specific protein in the virus, which helps stop the virus from multiplying. Although most data comes from studies on RSV, these findings suggest it could be effective.24567
Who Is on the Research Team?
Enanta Pharmaceuticals, Inc
Principal Investigator
Enanta Pharmaceuticals, Inc
Are You a Good Fit for This Trial?
This trial is for healthy adults who can participate in a study to understand how EDP-323 interacts with other drugs. Specific eligibility criteria are not provided, but typically participants should have no significant health issues that could affect the study's results.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive EDP-323, midazolam, caffeine, and rosuvastatin on respective dosing days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- EDP-323
Find a Clinic Near You
Who Is Running the Clinical Trial?
Enanta Pharmaceuticals, Inc
Lead Sponsor